Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Supportive Care

Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors

Chronic Pain

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact] — 23.9; 21.4; 41.7; 37.5 units on a scale — p=0.82

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Acceptance and Commitment Therapy (Behavioral); Treatment as Usual (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
Mar 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact]
62.6; 74.1; 73.9; 72.9 0.06
PRIMARY
The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact]
62.6; 74.1; 73.9; 72.9 0.06
SECONDARY
Number of Participants Who Want to Use Acceptance and Commitment Therapy as a Method for Treating Chronic Pain Post Active Cancer Treatment Active Cancer Treatment
19; 19; 18; 18; 14; 18
SECONDARY
The Degree to Which Patients Enjoy Using Acceptance and Commitment Therapy as a Method for Treating Chronic Pain Post Active Cancer Treatment: [Acceptability]
4.4; 4.5; 4.6; 4.6; 4.6; 4.6
SECONDARY
The Ability of Methodological Strategies Used to Monitor and Enhance the Reliability and Validity of ACT: [Fidelity]
100; 100; 100; 100; 100; 100

Summary

A study to help manage chronic pain in cancer survivors through Acceptance and Commitment Therapy (ACT) after undergoing active cancer treatment, such as surgery, chemotherapy, and/or radiation.

Eligibility Criteria

Inclusion Criteria

  • Provision to sign and date the consent form
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Be a male or female aged 18-100
  • Have pathology confirmed diagnosis of a solid tumor cancer
  • Be three or more months out from active cancer treatment (surgery, chemotherapy, and/or radiation)
  • Endorses experiencing pain for three or more months prior to eligibility screening
  • Indicates moderate to severe difficulties with pain interference as related to their cancer experience, with a score of 4 or higher on the pain interference item from the Chronic Pain Grading Questionnaire
  • Shows no evidence of cancer disease (NED) or with stable, chronic disease under "watchful waiting"
  • Fluent in English
  • Psychiatric stability as assessed by chart review and study personnel (e.g., not exhibiting symptoms consistent with diagnoses of serious mental illness such as active psychosis or mania)

Exclusion Criteria

  • Having pain that can be solely attributed to a diagnosis outside of their cancer experience
  • Presenting with barriers to group participation (e.g., social anxiety) or when group-based provision of care would impede participant's treatment or that of other group members
  • Patients with a diagnosis of malignant neoplasm of the brain (ICD-10 C71) or malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system (ICD-10 C72).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03661840). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search